Skip to main content
SpringerLink
Log in

Obesity and Renal Disease

  • Chapter
Obesity and Diabetes

Part of the book series: Contemporary Diabetes ((CDI))

  • 2279 Accesses

Abstract

With the increasing prevalence of obesity and its impact on metabolic and cardiovascular diseases, more attention is now being focused on the relationship between obesity and renal function. It is now recognized that obesity enhances the progression of renal function deterioration to end-stage renal disease (ESRD) in subjects with known preexisting renal disease. In addition, obestiy is associated with a well-described glomerulopathy called focal segmental glomerulosclerosis (FSGS). Finally, and most important, through its close association with type 2 diabetes and hypertension, the two most important causes of ESRD in the United States (1), obesity is now felt to be a major risk factor for the development of chronic kidney disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. USRDS: the United States Renal Data System. Am J Kidney Dis 2003;42(6)(Suppl 5):1–230.

    Google Scholar 

  2. Jennette JC, Charles L, Grubb W. Glomerulomegaly and focal segmental glomerulosclerosis associated with obesity and sleep-apnea syndrome. Am J Kidney Dis 1987;10(6):470–472.

    PubMed  CAS  Google Scholar 

  3. Bailey RR, Lynn KL, Burry AF, Drennan C. Proteinuria, glomerulomegaly and focal glomerulosclerosis in a grossly obese man with obstructive sleep apnea syndrome. Aust N Z J Med 1989;19(5):473, 474.

    PubMed  CAS  Google Scholar 

  4. Valensi P, Assayag M, Busby M, Paries J, Lormeau B, Attali JR. Microalbuminuria in obese patients with or without hypertension. Int J Obes Relat Metab Disord 1996;20(6):574–579.

    PubMed  CAS  Google Scholar 

  5. Ribstein J, du Callar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension 1995;26(4):610–615.

    PubMed  CAS  Google Scholar 

  6. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001;249(6):519–526.

    Article  PubMed  CAS  Google Scholar 

  7. Liese AD, Hense HW, Doring A, Stieber J, Keil U. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001;15(11):799–804.

    Article  PubMed  CAS  Google Scholar 

  8. Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59(4):1498–1509.

    Article  PubMed  CAS  Google Scholar 

  9. Hall JE, Kuo JJ, da Silva AA, de Paula RB, Liu J, Tallam L. Obesity-associated hypertension and kidney disease. Curr Opin Nephrol Hypertens 2003;12(2):195–200.

    Article  PubMed  CAS  Google Scholar 

  10. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003;41(3 Pt 2):625–633.

    Article  PubMed  CAS  Google Scholar 

  11. Bloomfield GL, Sugerman HJ, Blocher CR, Gehr TW, Sica DA. Chronically increased intra-abdominal pressure produces systemic hypertension in dogs. Int J Obes Relat Metab Disord 2000;24(7):819–824.

    Article  PubMed  CAS  Google Scholar 

  12. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. Ann NY Acad Sci 1999;892:91–107.

    Article  PubMed  CAS  Google Scholar 

  13. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens 2001;14(11 Pt 2):304S–309S.

    Article  PubMed  CAS  Google Scholar 

  14. Wofford MR, Anderson DC Jr, Brown CA, Jones DW, Miller ME, Hall JE. Antihypertensive effect of alpha-and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001;14(7 Pt 1):694–698.

    Article  PubMed  CAS  Google Scholar 

  15. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995;25(4 Pt 2):893–897.

    PubMed  CAS  Google Scholar 

  16. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334(5):292–295.

    Article  PubMed  CAS  Google Scholar 

  17. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension 1997;30(3 Pt 2):619–623.

    PubMed  CAS  Google Scholar 

  18. Jackson EK, Li P. Human leptin has natriuretic activity in the rat. Am J Physiol 1997;272(3 Pt 2):333–338.

    Google Scholar 

  19. Lembo G, Vecchione C, Fratta L, et al. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000;49(2):293–297.

    Article  PubMed  CAS  Google Scholar 

  20. Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002;51(1):168–173.

    Article  PubMed  CAS  Google Scholar 

  21. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998;31(1 Pt 2):409–414.

    PubMed  CAS  Google Scholar 

  22. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000;105(9):1243–1252.

    PubMed  CAS  Google Scholar 

  23. Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001;37(2 Pt 2):670–676.

    PubMed  CAS  Google Scholar 

  24. Correia ML, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI, Mark AL. The concept of selective leptin resisstance: evidence from agouti yellow obese mice. Diabetes 2002;51(2):439–442.

    Article  PubMed  CAS  Google Scholar 

  25. Rahmouni K, Haynes WG, Morgan DA, Mark AL. Selective resistance to central neural administration of leptin in agouti obese mice. Hypertension 2002;39(2 Pt 2):486–490.

    Article  PubMed  CAS  Google Scholar 

  26. Emdin M, Gataldelli A, Muscelli E, et al. Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss. Circulation 2001;103(4):513–519.

    PubMed  CAS  Google Scholar 

  27. Rocchini AP. Obesity hypertension, salt sensitivity and insulin resistance. Nutr Metab Cardiovasc Dis 2000;10(5):287–294.

    PubMed  CAS  Google Scholar 

  28. Hall JE. Hyperinsulinemia: a link between obesity and hypertension? Kidney Int 1993;43(6):1402–1417.

    Article  PubMed  CAS  Google Scholar 

  29. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998;95(5):2498–2502.

    Article  PubMed  CAS  Google Scholar 

  30. Fujiwara K, Hayashi K, Ozawa Y, Tokuyama H, Nakamura A, Saruta T. Renal protective effect of troglitazone in Wistar fatty rats. Metabolism 2000;49(10):1361–1364.

    Article  PubMed  CAS  Google Scholar 

  31. Hall JE, Brands MW, Dixon WN, Smith MJ Jr. Obesity-induced hypertension: renal function and systemic hemodynamics. Hypertension 1993;22(3):292–299.

    PubMed  CAS  Google Scholar 

  32. Engeli S, Sharma AM. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension. J Mol Med 2001;79(1):21–29.

    Article  PubMed  CAS  Google Scholar 

  33. Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001;15(14):2727–2729.

    PubMed  CAS  Google Scholar 

  34. Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis [see comments]. Kidney Int 1999;56(3):860–872.

    Article  PubMed  CAS  Google Scholar 

  35. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000;97(14):8015–8020.

    Article  PubMed  CAS  Google Scholar 

  36. Han DC, Isono M, Chen S, et al. Leptin stimulates type I collagen production in db/db mesangial cells: glucose uptake and TGF-beta type II receptor expression. Kidney Int 2001;59(4):1315–1323.

    Article  PubMed  CAS  Google Scholar 

  37. Ballermann BJ. A role for leptin in glomerulosclerosis? Kidney Int 1999;56(3):1154, 1155.

    Article  PubMed  CAS  Google Scholar 

  38. Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 2002;39(1):1–11.

    PubMed  CAS  Google Scholar 

  39. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998;31(1 Pt 2):181–188.

    PubMed  CAS  Google Scholar 

  40. Griffin KA, Abu-Amarah I, Picken M, Bidani AK. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 2003;41(2):201–206.

    Article  PubMed  CAS  Google Scholar 

  41. Kurtz TW. False claims of blood pressure-independent protection by blockade of the renin angiotensin aldosterone system? Hypertension 2003;41(2):193–196.

    Article  PubMed  CAS  Google Scholar 

  42. Anderson PW, Zhang XY, Tian J, et al. Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells. Kidney Int 1996;50(3):745–753.

    Article  PubMed  CAS  Google Scholar 

  43. Abrass CK, Spicer D, Raugi GJ. Induction of nodular sclerosis by insulin in rat mesangial cells in vitro: studies of collagen. Kidney Int 1995;47(1):25–37.

    Article  PubMed  CAS  Google Scholar 

  44. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319–336.

    Article  PubMed  CAS  Google Scholar 

  45. Zhou Y-T, Grayborn P, Karim A, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000;97:1784–1789.

    Article  PubMed  CAS  Google Scholar 

  46. Dwyer TM, Mizelle HL, Cockrell K, Buhner P. Renal sinus lipomatosis and body composition in hypertensive, obese rabbits. Int J Obes Relat Metab Disord 1995;19(12):869–874.

    PubMed  CAS  Google Scholar 

  47. Keane WF. The role of lipids in renal disease: future challenges. Kidney Int Suppl 2000;75:S27–S31.

    Article  PubMed  CAS  Google Scholar 

  48. Lyon CJ, Law RE, Huseh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003;144(6):2195–2200.

    Article  PubMed  CAS  Google Scholar 

  49. Lavaud S, Poirier B, Mandet C, et al. Inflammation is probably not a prerequisite for renal interstitial fibrosis in normoglycemic obese rats. Am J Physiol Renal Physiol 2001;280(4):683–694.

    Google Scholar 

  50. Baylis C, Atzpodien EA, Freshour G, Engels K. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003;307(3):854–860.

    Article  PubMed  CAS  Google Scholar 

  51. Dobrian AD, Davies MJ, Prewitt RL, Lauterio TJ. Development of hypertension in a rat model of diet-induced obesity. Hypertension 2000;35(4):1009–1015.

    PubMed  CAS  Google Scholar 

  52. Messerli FH, Christie B, DeCarvalho JG, et al. Obesity and essential hypertension: hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981;141(1):81–85.

    Article  PubMed  CAS  Google Scholar 

  53. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278(5):F817–F822.

    PubMed  CAS  Google Scholar 

  54. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002;324(3):127–137.

    Article  PubMed  Google Scholar 

  55. Wesson DE, Kurtzman NA, Frommer JP. Massive obesity and nephrotic proteinuria with a normal renal biopsy. Nephron 1985;40(2):235–237.

    PubMed  CAS  Google Scholar 

  56. Metcalf P, Baker J, Scott A, Wild C, Scragg R, Dryson E. Albuminuria in people at least 40 years old: effect of obesity, hypertension, and hyperlipidemia. Clin Chem 1992;38(9):1802–1808.

    PubMed  CAS  Google Scholar 

  57. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12(6):1211–1217.

    PubMed  CAS  Google Scholar 

  58. de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002;26(Suppl 4):21–24.

    Article  Google Scholar 

  59. Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephrotic syndrome: a complication of massive obesity. Ann Intern Med 1974;81(4):440–447.

    PubMed  CAS  Google Scholar 

  60. Praga M, Morales E, Herrero JC, et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999;33(1):52–58.

    PubMed  CAS  Google Scholar 

  61. Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med 1986;146(6):1105–1109.

    Article  PubMed  CAS  Google Scholar 

  62. Kasiske BL, Napier J. Glomerular sclerosis in patients with massive obesity. Am J Nephrol 1985;5(1):45–50.

    PubMed  CAS  Google Scholar 

  63. Praga M, Hernandez E, Morales E, et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 2001;16(9):1790–1798.

    Article  PubMed  CAS  Google Scholar 

  64. Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr 2001;138(4):481–485.

    Article  PubMed  CAS  Google Scholar 

  65. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60(3):1131–1140.

    Article  PubMed  CAS  Google Scholar 

  66. Zhang Z, Shahimtar S, Keane WF, et al. Importance of baseline distribution of proteinuria in renal outcome trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist (RENAAL) study. J Am Soc Nephrol 2005;16:1775–1780.

    Article  PubMed  CAS  Google Scholar 

  67. Praga M, Hernandez E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000;58(5):2111–2118.

    Article  PubMed  CAS  Google Scholar 

  68. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001;37(4):720–727.

    PubMed  CAS  Google Scholar 

  69. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63(1):225–232.

    Article  PubMed  Google Scholar 

  70. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003;14(4):479–487.

    PubMed  Google Scholar 

  71. Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer—a quantitative review. Br J Cancer 2001;85(7):984–990.

    Article  PubMed  CAS  Google Scholar 

  72. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000;343(18):1305–1311.

    Article  PubMed  CAS  Google Scholar 

  73. Morales E, Valero MA, Leon M, Hernandez E, Praga M. Beneficial effects of weight loss in over-weight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003;41(2):319–327.

    Article  PubMed  Google Scholar 

  74. Krebs JD, Evans S, Cooney L, et al. Changes in risk factors for cardiovascular disease with body fat loss in obese women. Diabetes Obes Metab 2002;4(6):379–387.

    Article  PubMed  CAS  Google Scholar 

  75. Metz JA, Stern JS, Kris-Etherton P, et al. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000;160(14):2150–2158.

    Article  PubMed  CAS  Google Scholar 

  76. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000;36(1):20–25.

    PubMed  CAS  Google Scholar 

  77. Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001;134(1):1–11.

    PubMed  CAS  Google Scholar 

  78. Fagerberg B, Andersson OK, Isaksson B, Bjorntorp P. Blood pressure control during weight reduction in obese hypertensive men: separate effects of sodium and energy restriction. Br Med J (Clin Res Ed) 1984;288(6410):11–14.

    Article  CAS  Google Scholar 

  79. Seals DR, Tanaka H, Clevenger CM, et al. Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: role of arterial stiffness. J Am Coll Cardiol 2001;38(2):506–513.

    Article  PubMed  CAS  Google Scholar 

  80. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003;14(6):1480–1486.

    Article  PubMed  Google Scholar 

  81. Haciyanli M, Erkan N, Bora S, Gulay H. Vertical banded gastroplasty in the Aegean region of Turkey. Obes Surg 2001;11(4):482–486.

    Article  PubMed  CAS  Google Scholar 

  82. Torgerson JS, Sjostrom L. The Swedish Obese Subjects (SOS) study—rationale and results. Int J Obes Relat Metab Disord 2001;25(Suppl 1):S2–S4.

    Article  PubMed  Google Scholar 

  83. Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002;40(6):781–788.

    Article  PubMed  CAS  Google Scholar 

  84. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861–869.

    Article  PubMed  CAS  Google Scholar 

  85. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004;43(1):41–47.

    Article  PubMed  CAS  Google Scholar 

  86. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004;43(1):48–56.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT

    Ayman Geneidy MD

  2. University of Vermont College of Medicine, Fletcher Allen Health Care, Burlington, VT

    Richard Solomon MD

Authors
  1. Ayman Geneidy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Solomon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Diabetes & Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Christos S. Mantzoros MD, DSc

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Geneidy, A., Solomon, R. (2006). Obesity and Renal Disease. In: Mantzoros, C.S. (eds) Obesity and Diabetes. Contemporary Diabetes. Humana Press. https://doi.org/10.1007/978-1-59259-985-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-985-1_18

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-538-5

  • Online ISBN: 978-1-59259-985-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation